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Abstract
Background: Neurotoxicity caused by treatment for a brain tumor is a major cause of neurocognitive decline in
survivors. Studies have shown that neurofeedback may enhance neurocognitive functioning. This paper describes
the protocol of the PRISMA study, a randomized controlled trial to investigate the efficacy of neurofeedback to
improve neurocognitive functioning in children treated for a brain tumor.
Methods/Design: Efficacy of neurofeedback will be compared to placebo training in a randomized controlled
double-blind trial. A total of 70 brain tumor survivors in the age range of 8 to 18 years will be recruited. Inclusion
also requires caregiver-reported neurocognitive problems and being off treatment for more than two years. A
group of 35 healthy siblings will be included as the control group. On the basis of a qEEG patients will be assigned
to one of three treatment protocols. Thereafter patients will be randomized to receive either neurofeedback
training (n=35) or placebo training (n=35). Neurocognitive tests, and questionnaires administered to the patient,
caregivers, and teacher, will be used to evaluate pre- and post-intervention functioning, as well as at 6-month
follow-up. Siblings will be administered the same tests and questionnaires once.
Discussion: If neurofeedback proves to be effective for pediatric brain tumor survivors, this can be a valuable
addition to the scarce interventions available to improve neurocognitive and psychosocial functioning.
Trial registration: ClinicalTrials.gov NCT00961922.
Keywords: Brain tumor, Child, Survivors, Attention, Memory, Processing speed, Neurocognitive functioning,
Intervention, Neurofeedback, Protocol, RCT, Double-blind
Background
As a result of improved treatment, the survival rate of
children diagnosed with a brain tumor has increased
considerably [1]. As a consequence, neurocognitive long-
term effects of the tumor and the treatment are reported
more often, including deficits in attention, processing
speed, and memory [2-4]. Radiotherapy, chemotherapy,
tumor location, and longer time since diagnosis are
related to worse neurocognitive functioning [5,6]. A
major consequence of these impairments is the decline
in ability to acquire new skills and information, which
leads to an increasing gap in the development between
patients and their peers. This, in turn, has its impact on
educational results, vocational success and may com-
promise social competence and quality of life [7].
Butler and Mulhern have emphasized that interven-
tions should be developed to improve neurocognitive
functioning and subsequently improve future perspec-
tives of these children [8]. Interventions that are consid-
ered relevant for survivors with cancer-related brain injury
are cognitive remediation and pharmacotherapy [9,10].
A cognitive remediation program, using techniques from
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three disciplines: brain injury rehabilitation, special educa-
tion and clinical psychology, has been developed and tested
by Butler and colleagues [9]. Participants in the randomized
controlled trial were 161 survivors of a childhood cancer,
whose malignancy and/or treatment involved the central
nervous system. The results showed improvements in care-
giver reported attention and academic achievement, al-
though the effect sizes were modest. Van ‘t Hooft et al.
have investigated the effects of a cognitive training program
on neurocognitive function with a randomized controlled
trial, enrolling 38 patients with acquired brain injury, in-
cluding 14 brain tumor survivors [10]. The training pro-
gram consisted of memory and attention exercises, in
combination with cognitive behavioral training. The chil-
dren in the treatment group showed sustained positive
effects on memory and attention functioning until six
months after the training, but not on processing speed.
Regarding pharmacotherapy, it has been suggested that
survivors of childhood cancer may benefit from stimu-
lant medication as used in the treatment of attention
deficit hyperactivity disorder (ADHD). Attention deficits
in survivors of brain tumors are likely to improve by me-
thylphenidate. Mulhern and colleagues found improve-
ments of attention in 37 long term survivors of a
malignant brain tumor after methylphenidate [11]. In a
randomized placebo-controlled double-blinded trial in-
cluding 32 survivors of a brain tumor (n=25) or acute
lymphoblastic leukemia (n=7), Thompson et al. found
that methylphenidate led to improved sustained atten-
tion [12]. A drawback of pharmacotherapy is the possi-
bility of side effects, e.g. sleep disturbance, weight loss,
anxiety, and sadness [13]. Also, this medication does not
lead to a sustained effect unless the patient continues
the pharmacotherapy.
The limited current available options warrant the
search for alternatives. Neurofeedback is a relatively new
form of therapy, which has never been investigated in
pediatric brain tumor survivors. Neurofeedback is a be-
havioral intervention that is based on the principles of
operant conditioning. During the therapy the patient is
presented with real-time feedback on his or her brain-
waves, as measured by one or more electrodes on the
scalp. The patient is reinforced when the brain produces
a certain desired wave. Reinforcement may comprise
seeing a movie or hearing music. The desired brain wave
is determined by a quantified electro encephalogram
(qEEG), which is conducted prior to the training.
The effects of neurofeedback have been discovered
serendipitously by Sterman, when cats having received
feedback of 12–15 Hz on the motor cortex showed to be
less susceptible to epileptic seizures [14]. There is a large
body of scientific research documenting the effectiveness
of neurofeedback for the treatment of diverse patho-
logical conditions as summarized in comprehensive
reviews, including ADHD, traumatic brain injury and
schizophrenia [15-19].
Strehl et al. showed that children with ADHD were
able to learn to regulate their brain activity by neuro-
feedback [20]. After training, significant improvements
in behavior, attention, and IQ scores were found. All
changes proved to be stable at six months follow-up
after the end of training. Hodgson et al. conclude in
their meta-analysis on nonpharmacological interventions
for ADHD that neurofeedback resulted in significant
improvements of DSM-IV symptoms of ADHD, neuro-
cognitive functioning and behavior [18]. In a compara-
tive study researchers found that the positive effects of
neurofeedback for children with ADHD were superior
to a computerized attention training at six months
follow up [21]. However, to date there is a lack of
published studies that employ a randomized placebo-
controlled double-blind design when investigating neu-
rofeedback [22].
Brain tumor survivors differ from ADHD patients, as
they have structural brain damage caused by the tumor,
surgery, radiotherapy and/or chemotherapy. An indica-
tion that neurofeedback might be effective in pediatric
brain tumor survivors may be derived from the results
of studies into the effects of neurofeedback in patients
with traumatic brain injury. A review of Thornton and
colleagues [23] describes a total of 44 studies (12 RCT,
16 comparative, 16 correlation) with traumatic brain in-
jury patients reporting improved attention, cognitive
flexibility, cognitive performance, and problem solving
after neurofeedback, providing strong initial support for
the idea that neurofeedback could be used in patients
with structural brain damage. Subsequently, Aukema
and colleagues conducted a pilot study into the feasi-
bility of neurofeedback on 9 brain tumor survivors in
our hospital [24]. This study demonstrated that it was
feasible to use neurofeedback with brain tumor survi-
vors. All participants completed the training and were
positive about the training they received, as they
would recommend it to others. Patients reported
decreased subjective fatigue after the training. Also
the test results showed that processing speed improved
in 6 out of 9 patients. These findings warranted the set up
of a larger study into the effectiveness of neurofeedback
for pediatric brain tumor survivors.
The current paper describes the protocol of the
PRISMA study (pediatric research on improving speed,
memory, and attention); a randomized controlled
double-blind trial, approved by the medical ethical com-
mittee of the Academic Medical Centre in Amsterdam.
The primary aim of the PRISMA study is to investigate
the efficacy of neurofeedback for improving neurocognitive
functioning after treatment for a pediatric brain tumor.
Secondary, we hypothesize that subsequent to the expected
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neurocognitive changes achieved with neurofeedback, chil-
dren will experience improved psychosocial functioning
[25]. Neurocognitive functioning will be investigated by
tests administered to the patient. Psychosocial functioning
will be measured using patient-reported as well as care-
giver and teacher reported questionnaires. Assessments
will take place pre and post training, as well as six
months post training, in order to examine the long-
term effects of the training. Comparing the effects of
neurofeedback to placebo feedback will assess efficacy
of neurofeedback. Pre training results obtained with the
brain tumor survivors will be compared to a control
group of healthy siblings, to assess the level of dysfunc-
tion on the measures used in this study.
Methods
Study design
This study is a randomized placebo-controlled double-
blind trial, to investigate whether neurofeedback
improves neurocognitive functioning in children who
have received treatment for a brain tumor (trial number
clinicaltrials.gov NCT00961922). After enrollment,
patients will be randomized into two groups: (1a) the ex-
perimental group, receiving neurofeedback, and (1b) the
placebo group, receiving placebo training. In addition,
(2) a control group of healthy siblings is included; this
group will not receive any training. If effectiveness of
neurofeedback is demonstrated after completion of the
study, patients in the placebo group will be given the o-
pportunity to receive neurofeedback.
Participants
Eligible for inclusion are patients in the Netherlands,
aged 8 to 18 years, who finished treatment for a brain
tumor at least two years prior to enrolment and who
suffer from problems in neurocognitive functioning.
Problems in neurocognitive functioning include atten-
tion problems, problems with information processing
speed and/or memory problems as assessed by caregiver
report. Exclusion criteria are premorbid diagnosis of
ADHD or ADD, a mental or physical condition that pro-
hibits neurocognitive assessment and insufficient mas-
tery of the Dutch language. Siblings, aged between 8 and
18 years, form the control group.
Intervention
The neurofeedback training is performed at home or
school using a Dell notebook (Inspiron N5030, 15.6 inch
screen), with BioExplorer software, version 1.5 installed,
and a portable Brainquiry PET neurofeedback device
[26,27]. Reinforcement is provided by a self-selected
movie that will be presented on the screen if the brain
produces the desired activity, as detected by an electrode
placed at Cz (see Figure 1). Each patient receives two
sessions weekly for 15 weeks, 30 sessions in total. Each
session takes 39 minutes to administer, divided in ten
blocks of three-minutes training, alternated with one-
minute breaks. In the breaks the patient will be
instructed to sit quietly with the eyes closed.
The neurofeedback sessions are hosted by extensively
trained research assistants who have successfully com-
pleted a full day schooling session on administration of
the neurofeedback training in accordance with detailed
standard operating procedures. During the first neuro-
feedback session, the research assistant will be accom-
panied by one of the researchers to ensure adherence to
the standard operating procedures. After each session,
the research assistant is required to fill out a checklist
providing information about the training that includes
items on start and finish time of the training, duration
of the session, selected movie, alertness of the patient,
and any deviations from the standard procedures.
Checklists are e-mailed to the researchers on a weekly
basis.
Neurofeedback treatment modules
The neurofeedback treatment modules were developed
in the software program BioExplorer. To increase com-
parability, we decided to develop three standard treat-






Figure 1 EEG locations. Patients in PRISMA are trained on
location Cz. Location Cz is the location exactly halfway between
the nasion (the bridge of the nose) and the inion (the most
prominent point on the lower rear of the skull) and halfway
between the two ears.
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[24], rather than designing an individualized treatment
module for each participant. The three treatment mo-
dules are (1) beta 1 up training, (2) sensory motor
rhythm (SMR) up/beta 1 down training, and (3) beta 1
down training. The qEEG of the patient determines
the most suitable of the three neurofeedback treat-
ment modules. The mean Z-score for the power in the
beta 1 frequency band (15–20 Hz) for the electrodes on
locations Fcz, Cz, C3, C4 and Cpz are calculated (see
Figure 1). For SMR no Z-scores are provided in the
brain resource report. SMR power is calculated and
p-values are obtained over the average of 9 electrodes
(F3, Fz, F4, C3, Cz, C4, P3, Pz and P4). The beta 1 up
training is given if the beta 1 power is within the nor-
mal range (within 1 standard deviation from the mean)
or lowered (more than 1 standard deviation below the
mean). The SMR up/beta 1 down training is chosen if
the beta 1 power is elevated (more than 1 standard de-
viation above the mean) and SMR (12–15 Hz) is within
the normal range (p>0.05) or lowered (p<0.05). The
beta 1 down training is chosen if the patient has beta
spindles, ascertained by an EEG specialist via observa-
tion, or if both beta 1 is elevated (more than 1 standard
deviation above the mean) and SMR power is elevated
(p<0.05). Three identical placebo treatment modules
were matched to the three neurofeedback treatment
modules; beta 1 up placebo, SMR up/beta 1 down pla-
cebo and beta 1 down placebo. In the placebo treat-
ment modules, the provided reward of a movie is not
based on the desired brain waves from the patient, but
on the ‘random signal generator’ that is incorporated in
the BioExplorer software.
All treatment modules are set at an automatic threshold
of 80% reward. This means that the threshold of reward is
regularly adjusted in a way that the child sees the movie
approximately 80% of the time and 20% of the time the
screen of the laptop briefly turns black. Elevated muscular
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Figure 2 Flow chart of the PRISMA study.
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a lamp) can decrease the quality of the training; therefore
we employ a threshold of 10 μV for muscular tension
(> 55 Hz) and 50 μV for noise (range 48–52 Hz). If the
muscular tension and/or the noise reach above the thres-
hold, the movie is interrupted and the computer makes a
beeping sound. The training will not continue until the
muscular tension and/or noise are brought back under the
threshold. This applies to the neurofeedback treatment
modules as well as the placebo treatment modules.
Randomization
The three neurofeedback treatment modules and three
placebo treatment modules have been designed to have the
exact same appearance on the screen of the notebook, in
order to be indistinguishable during training. The six treat-
ment modules have randomly been assigned a number
(treatment module 1–6). J.O., one of the members of the
research team, holds the key to the codes; the other mem-
bers are blinded. Another member of the research team
analyzes the qEEG and informs J.O. which of the three
neurofeedback treatment modules is indicated according
to the protocol (see Figure 2). J.O. is then responsible for
randomizing the patient into the actual neurofeedback or
the placebo training using a randomization table generated
by SPSS. For stratfication purposes, randomization takes
place after selection of the most appropriate neurofeedback
treatment module. After randomization, J.O. notifies M.d.
R. of the assigned treatment module (treatment module
1–6) and M.d.R. sends the assigned treatment module via
email to the designated research assistant providing the
neurofeedback training. Due to his not-blind status, J.O. is




Five out of seven Dutch University hospitals accepted the
invitation to join the study. Participating hospitals are the
Emma children’s hospital/Academic Medical Centre in
Amsterdam, VU medical centre in Amsterdam, university
medical centre Utrecht in Utrecht, St. Radboud university
medical centre in Nijmegen and university medical centre
Maastricht in Maastricht. A letter via their oncologist or
psychologist informs patients and their caregivers about
the study. Interested caregivers will be provided with a
screening questionnaire concerning their child’s neurocog-
nitive functioning (including items on attention function-
ing, memory and speed) and exclusion criteria
Table 1 Outcomes, measures and to whom it is administered
Neurocognitive assessment Measurement T0 T1 T2
Attention Attention Network task (ANT) [28] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Processing speed Baseline Speed ANT [28] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Memory Visual Sequencing task Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Digit Span (age appropriate Wechsler scale) [29,30] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Intellectual functioning Abbreviated WISC-III* [29] Patient/sibling (8–16) - Patient (8–16)
Abbreviated WAIS-III* [30] Patient/sibling (17–18) - Patient (17–18)
Inhibition Stop Signal task [31] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Visuomotor integration Tracking and Pursuit task Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Questionnaires
Social/emotional functioning SDQ child version [32] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
SDQ parent version [32] Caregiver (8–18) Caregiver (8–18) Caregiver (8–18)
SDQ teacher version [32] Teacher (8–18) Teacher (8–18) Teacher (8–18)
Self esteem Dutch version SPPC [33] Patient/sibling (8–11) Patient (8–11) Patient (8–11)
Dutch version SPPA [34] Patient/sibling (12–18) Patient (12–18) Patient (12–18)
Health related quality of life Kidscreen 27 [35] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Fatigue CIS [36] Patient/sibling (8–18) Patient (8–18) Patient (8–18)
Sleep disorder SDSC [37] Caregiver (8–18) Caregiver (8–18) Caregiver (8–18)
Attention SWAN [38] Caregiver (8–18) Caregiver (8–18) Caregiver (8–18)
Executive functioning BRIEF parent version [39] Caregiver (8–18) Caregiver (8–18) Caregiver (8–18)
BRIEF teacher version [39] Teacher (8–18) Teacher (8–18) Teacher (8–18)
Note: Intellectual functioning is assessed at T0 and T2 but not at T1. Siblings are assessed at T0 only.
*The following subtasks were administered: Arythmic, Similarities, Block Design, and Picture Completion.
SDQ = Strengths and Difficulties Questionnaires; SPPC/SPPA = Self Perception Profile for Children/Adolescents; CIS = Checklist Individual Strength; Sleep
Disturbance Scale for Children; SWAN = Strengths and Weaknesses of ADHD-symptoms and Normal-behavior; BRIEF = Behavior Rating Inventory of Executive
Functioning; WISC-III = Wechsler Intelligence Scale for Children – Third version; WAIS-III = Wechsler Adult Intelligence Scale – Third version.
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(e.g. premorbid diagnosis of ADHD or ADD) to verify eli-
gibility of the patient. If eligible for inclusion, the patient is
invited for the pre training assessment. If applicable, a sib-
ling will also be invited for assessment to participate in the
control group. On the day of the pre training assessment,
the informed consent form is signed by caregivers, the
patient, and if applicable, the sibling.
Assessment
Assessments are conducted at one of the three cooperat-
ing EEG centers in the Netherlands; Pels institute in
Amsterdam, Brainfact in Amsterdam, and EEG resource
institute in Nijmegen. Patients are assessed on three
occasions: pre training (T0), directly post training (T1),
and six months post training (T2); see Figure 2. Assess-
ments include neurocognitive testing, questionnaires
filled out by patient, caregiver, and teacher, and a qEEG,
see Table 1. Assessment of the siblings occurs only once,
and is identical to the assessments used in patients with
the exception of questionnaires filled out by parents and
teachers.
qEEG An EEG is recorded from the patients at three
time points. A Quick-cap with NuAmp 10–20 electrodes
international system from neuroscan is used, with 28
channels [40]; Fp1, Fp2, F7, F3, Fz, F4, F8, FC3, FCz,
FC4, T3, C3, Cz, C4, T4, CP3, CPz, CP4, T5, P3, Pz, P4,
T6, O1, Oz and O2. During the first three minutes an
eyes-open resting EEG is registered, in the consecutive
three minutes an eyes-closed resting EEG. After the rest-
ing EEG, event related potentials are measured during
an odd ball and a go-nogo task. The Brain Resource
International Database (BRID) [41,42], comprising EEG
power spectra of over 4.000 healthy controls, provides
normative data to quantify the EEG (qEEG) and obtain
Z-scores for the participants in the current study.
Neurocognitive tests To objectify the primary hypothesis
of the study, that neurofeedback will improve neurocogni-
tive functioning, different neurocognitive domains are
assessed. The tests are conducted by one of the researchers
or extensively trained research assistants and take approxi-
mately two and a half hours. Based on literature describing
late effects in brain tumor patients, the following neurocog-
nitive domains were targeted for assessment [43]: attention,
processing speed, memory, intellectual functioning,
inhibition, and visuomotor integration. Well-validated
computerized and pencil-and-paper tests were selected
to provide a comprehensive assessment of neurocogni-
tive functioning before the training and the efficacy of
neurofeedback (see Table 1).
Questionnaires Our secondary hypothesis regards
the impact of neuropsychological performance on
psychosocial functioning [25,44]. Based on studies
reports, the following domains are assessed using ques-
tionnaires: social/emotional functioning, self-esteem, and
health related quality of life. Because of the reported de-
crease in fatigue after training in the pilot study, we also
included questionnaires assessing fatigue and sleep dis-
turbance [24]. In addition, two questionnaires on atten-
tion and executive functioning were added to assess
caregiver and teacher rated neurocognitive functioning.
Widely used, reliable, and validated questionnaires were
selected in order to assess the domains of interest, as
well as the effect of neurofeedback on these domains
(see Table 1). Questionnaires were administered to either
patient, caregivers or teacher, if applicable. The online
questionnaires take approximately 30 minutes to fill out.
In addition, as an interim measurement, caregivers fill in
the attention questionnaire (SWAN [44]) one extra time,
after the first 10 sessions of the patient.
Power calculation
Power calculations used the neurocognitive measures as
primary outcome measures. The calculations were done
in the statistical program nQuery Advisor [45]. We ex-
pect that the neurofeedback will have a medium (d=0.5)
to large effect (d=0.8) on neurocognitive functioning as
measured at T1 and compared to T0, based on improve-
ments found in children with ADHD who were trained
with neurofeedback and on the improvements found in
learning-impaired childhood cancer survivors treated
with methylphenidate [12,15]. Given an effect size of 0.6
with alpha set at 0.05 (one-sided) and a power of 0.80, a
minimum of 35 patients is required in both the neuro-
feedback group and the placebo group.
Statistical analyses
Intention-to-treat analyses will be conducted. Because of
possible withdrawal before treatment starts, dropouts
during the study, failure to fill out questionnaires, or re-
search procedure violations, missing data will occur. Im-
putation of missing values will be carried out as much as
possible to make intention-to-treat analyses feasible.
Missing data will be imputed using Imputation and
Variance Estimation Software [46].
Prior to the training (T0) we will assess differences
between patients and siblings on neurocognitive and
psychosocial functioning, using mixed modelling.
Subsequently, we will conduct multivariate analysis of
variance (MANOVA) to determine the effect of neu-
rofeedback post-treatment (T1) on the primary and
secondary outcomes, comparing the patients in the
neurofeedback group to the patients in the placebo
group. To control for possible differences in neurocog-
nitive functioning prior to the training, T0 data will be
included in the model as covariate. Finally, we will use
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repeated measures analysis for group (neurofeedback
and placebo) x time (T0, T1, and six months follow-up,
T2) to investigate the changes over time. To examine
the possible effects of patient characteristics on the
efficacy of the neurofeedback, the following variables
will be assessed as covariates in the MANOVA and
repeated measures analyses: age at assessment, age at
diagnosis, diagnosis, time since diagnosis, and treat-
ment modalities. All analyses will be conducted using
SPSS. A P-value <0.05 will be considered significant.
Discussion
This article describes the design of the PRISMA study, a
randomized controlled trial investigating the efficacy of
neurofeedback in pediatric brain tumor survivors with
neurocognitive problems. Although neurocognitive pro-
blems in pediatric oncology survivors are reported in
numerous studies, empirically validated interventions
addressing these deficits are scarce. There is growing
evidence for neurofeedback as a valuable treatment in
different brain disorders [15,21]. Our study is the first to
investigate the efficacy of neurofeedback in pediatric
brain tumor survivors using a randomized placebo-
controlled double-blind trial, comparing neurofeedback
to placebo training. By setting an automatically adjusted
threshold of feedback as opposed to a manually adjusted
threshold, we enabled blinding the trainers; trainers were
not required to monitor the brain activity of the patient
during the sessions. Furthermore, we ensure the
standardization of the neurofeedback treatment by
employing carefully instructed research assistants pro-
viding the neurofeedback treatment. At the same time
we increased the feasibility for the patients, by adminis-
tering the training at the patients' home or school. In
addition, the effects of neurofeedback on neurocogni-
tive and psychosocial functioning are thoroughly
investigated by using well-validated paradigms and
psychometrically sound questionnaires administered
to patient, caregiver and teacher. Lastly, we have
included a control group of healthy siblings, to com-
pare performance of the brain tumor survivors to chil-
dren without a history of a brain tumor.
The design of PRISMA has some methodological pit-
falls to take into account. Because of time factors and
the population, this study might be at risk for losing
patients during the treatment phase and during follow-
up. With five year survival rates of approximately 65%,
some patients may relapse [47], or they may discontinue
their participation in the study. We increase comparability
by employing three different training modules; however,
the training might be less effective than an individualized
training. The groups receiving each of the three treatment
modules are small. Also, the group of brain tumor patients
is heterogeneous, e.g. in terms of tumor diagnosis, tumor
location, age at diagnosis, treatment, time since diagnosis,
and time since end of treatment. It is well documented
that these variables play an important role in neurocogni-
tive outcomes. These heterogeneities may be reflected in
our results.
In conclusion, if neurofeedback proves to be effective
in improving neurocognitive deficits after treatment for
a brain tumor, this would be a valuable addition to the
currently available effective interventions for this vulner-
able group of pediatric brain tumor survivors.
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